Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) rose 1.2% on Tuesday . The stock traded as high as $65.34 and last traded at $62.29. Approximately 8,355,728 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 10,424,641 shares. The stock had previously closed at $61.54.
Analysts Set New Price Targets
TEM has been the subject of several analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Loop Capital cut their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.36.
Check Out Our Latest Report on Tempus AI
Tempus AI Price Performance
Insider Transactions at Tempus AI
In related news, Director David R. Epstein sold 620 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total value of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,037,702 shares of company stock valued at $89,449,651 in the last three months.
Institutional Trading of Tempus AI
Hedge funds and other institutional investors have recently modified their holdings of the company. IFP Advisors Inc acquired a new position in Tempus AI during the fourth quarter worth $76,000. First Horizon Advisors Inc. increased its stake in Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after acquiring an additional 1,108 shares during the period. Sigma Planning Corp boosted its holdings in Tempus AI by 43.9% during the fourth quarter. Sigma Planning Corp now owns 33,638 shares of the company’s stock valued at $1,136,000 after purchasing an additional 10,269 shares in the last quarter. Private Advisor Group LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $1,344,000. Finally, Apollon Wealth Management LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $256,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
- Five stocks we like better than Tempus AI
- Growth Stocks: What They Are, Examples and How to Invest
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Airline Stocks – Top Airline Stocks to Buy Now
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.